Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: GRFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.53
1 Year Target Price $12.53
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.13% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.65B USD | Price to earnings Ratio 13.81 | 1Y Target Price 12.53 |
Price to earnings Ratio 13.81 | 1Y Target Price 12.53 | ||
Volume (30-day avg) 2 | Beta 1.19 | 52 Weeks Range 6.09 - 10.96 | Updated Date 11/14/2025 |
52 Weeks Range 6.09 - 10.96 | Updated Date 11/14/2025 | ||
Dividends yield (FY) 2.02% | Basic EPS (TTM) 0.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.96% | Operating Margin (TTM) 20.43% |
Management Effectiveness
Return on Assets (TTM) 4.58% | Return on Equity (TTM) 5.89% |
Valuation
Trailing PE 13.81 | Forward PE 11.52 | Enterprise Value 17744561401 | Price to Sales(TTM) 1.01 |
Enterprise Value 17744561401 | Price to Sales(TTM) 1.01 | ||
Enterprise Value to Revenue 2.01 | Enterprise Value to EBITDA 9.27 | Shares Outstanding 258223736 | Shares Floating 535070698 |
Shares Outstanding 258223736 | Shares Floating 535070698 | ||
Percent Insiders - | Percent Institutions 58.09 |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols SA is a global healthcare company founded in 1940 in Barcelona, Spain. It is a pioneer in the plasma derivatives industry. Key milestones include its expansion into the United States, the development of innovative therapies, and its listing as an ADR on Nasdaq. Grifols has evolved into a leading biopharmaceutical company focused on improving human health through the development of plasma-derived medicines, diagnostic solutions, and hospital supplies.
Core Business Areas
- Bioscience: This division is Grifols' largest and focuses on the production and commercialization of plasma-derived protein therapies for treating rare, chronic diseases such as hemophilia, immune deficiencies, and alpha-1 antitrypsin deficiency. It also includes the donation and fractionation of human plasma.
- Hospital: This division provides innovative solutions to hospitals and healthcare facilities. Its offerings include specialized hospital supplies, integrated pharmacy services, and sterilization solutions, aiming to improve patient care and operational efficiency.
- Diagnostic: This division develops and manufactures in-vitro diagnostic products and solutions. These include blood typing reagents, instruments for blood transfusion centers, and molecular diagnostic tests, contributing to safer blood transfusions and disease detection.
Leadership and Structure
Grifols SA is a publicly traded company with a board of directors and a management team responsible for its strategic direction and operations. The company is family-controlled, with the Grifols family holding a significant stake and maintaining active roles in leadership.
Top Products and Market Share
Key Offerings
- Competitors: CSL Behring,Takeda Pharmaceutical Company,Octapharma
- Description: A plasma protein used to restore blood volume and treat conditions like shock, burns, and liver disease. Grifols is a major global supplier of albumin.
- Market Share: Significant, though precise percentage is proprietary. Competitors include CSL Behring, Takeda Pharmaceutical Company, and Octapharma.
- Product Name 1: Albumin (e.g., Albu-Ready, Grifols Albumin)
- Competitors: CSL Behring,Takeda Pharmaceutical Company,Shire
- Description: Used to treat primary immunodeficiencies, neurological disorders, and autoimmune diseases. Grifols has a strong portfolio in this segment.
- Market Share: Substantial, with significant global presence. Key competitors are CSL Behring, Takeda Pharmaceutical Company, and Shire (now part of Takeda).
- Product Name 2: Immunoglobulins (e.g., Flebogamma, Gammagard)
- Competitors: Roche,CSL Behring,Shire
- Description: Plasma proteins used to treat hemophilia A and B, respectively. Grifols offers a range of these essential therapies.
- Market Share: Competitive, with other major players in the hemophilia market. Major competitors include Roche, CSL Behring, and Shire.
- Product Name 3: Clotting Factors (e.g., Factor VIII, Factor IX)
Market Dynamics
Industry Overview
Grifols operates in the biopharmaceutical and healthcare sectors, primarily focusing on plasma-derived therapies and diagnostic solutions. The industry is characterized by high R&D investment, stringent regulatory environments, and a growing demand for treatments for rare diseases and chronic conditions. The plasma collection and fractionation market is competitive and relies heavily on donor recruitment and retention.
Positioning
Grifols is a leading global player in the plasma derivatives market, recognized for its expertise in plasma fractionation and its broad portfolio of life-saving therapies. Its vertically integrated model, from plasma collection to finished product, provides a competitive advantage. The company also has a strong presence in hospital solutions and diagnostic products.
Total Addressable Market (TAM)
The global market for plasma-derived therapies is substantial and growing, estimated to be tens of billions of dollars annually and projected to continue expanding due to aging populations, increasing prevalence of chronic diseases, and advancements in treatment. Grifols is well-positioned to capture a significant portion of this TAM due to its established infrastructure, R&D capabilities, and global reach.
Upturn SWOT Analysis
Strengths
- Strong global presence and established distribution networks.
- Vertically integrated business model (plasma collection to finished product).
- Leadership position in plasma-derived therapies.
- Diversified product portfolio across bioscience, hospital, and diagnostic segments.
- Significant R&D investment and pipeline.
Weaknesses
- High reliance on plasma donations, which can be subject to supply fluctuations.
- Intense competition in key therapeutic areas.
- Complex regulatory landscape that can impact product development and approval timelines.
- Geopolitical and economic risks affecting global operations.
- Recent accounting and governance concerns have impacted investor confidence.
Opportunities
- Growing demand for plasma-derived therapies driven by an aging population and unmet medical needs.
- Expansion into emerging markets with increasing healthcare spending.
- Development of novel therapies and treatments through R&D.
- Strategic acquisitions to enhance product portfolio or market access.
- Advancements in biotechnology and manufacturing processes.
Threats
- Intensifying competition from existing and new players.
- Changes in healthcare policies and reimbursement rates.
- Volatile plasma supply due to donor recruitment challenges or public health crises.
- Patent expirations and the emergence of biosimilar competition.
- Negative publicity and scrutiny related to financial reporting or governance.
Competitors and Market Share
Key Competitors
- CSL Limited (CSL)
- Takeda Pharmaceutical Company Limited (TAK)
- Haleon plc (HLN)
Competitive Landscape
Grifols competes in a highly specialized and capital-intensive industry. Its advantages lie in its integrated supply chain, established reputation, and diverse product portfolio. However, competitors like CSL often have larger market shares and R&D budgets. Haleon operates in a broader consumer healthcare space but has products that overlap in certain therapeutic areas.
Major Acquisitions
Biotest AG
- Year: 2022
- Acquisition Price (USD millions): 1670
- Strategic Rationale: To strengthen its position in plasma-derived therapies, expand its product portfolio, and gain access to Biotest's plasma collection network and R&D capabilities, particularly in Europe.
Growth Trajectory and Initiatives
Historical Growth: Grifols has demonstrated a consistent historical growth trajectory, primarily fueled by its Bioscience segment and strategic acquisitions. The company has expanded its plasma collection capacity and diversified its therapeutic offerings over the years.
Future Projections: Analyst projections for Grifols' future growth are typically positive, driven by the increasing demand for plasma-derived therapies and the company's ongoing R&D efforts. Growth is expected to be supported by new product launches and market expansion. However, projections can be subject to change based on market conditions and company-specific performance.
Recent Initiatives: Recent initiatives have focused on strengthening its plasma supply chain, investing in new manufacturing technologies, and exploring strategic partnerships. The company has also been focused on improving its financial transparency and corporate governance following past issues.
Summary
Grifols SA ADR is a leading global biopharmaceutical company with a strong foundation in plasma-derived therapies. Its vertically integrated model and diverse product offerings are key strengths, positioning it well in a growing market. However, the company faces challenges related to plasma supply volatility, intense competition, and recent governance concerns which require careful management. Continued investment in R&D and strategic focus on operational excellence will be crucial for sustained growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Grifols SA Investor Relations
- SEC Filings (10-K, 20-F)
- Financial News Websites (e.g., Reuters, Bloomberg)
- Market Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may not be exhaustive or perfectly up-to-date. Users are advised to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23800 | Website https://www.grifols.com |
Full time employees 23800 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.